Drug interactions
Dipyridamole + Encorafenib
Severity: Minor
Dipyridamole and Encorafenib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Encorafenib may inhibit BCRP, and dipyridamole is a BCRP substrate. Exposure to dipyridamole could rise modestly, increasing its vasodilatory effects such as headache, hypotension and dizziness.
What this interaction means in plain words
Dipyridamole and Encorafenib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Dipyridamole belongs to Cardiovascular; Encorafenib belongs to Oncology.
Why it happens
Inhibition of BCRP efflux transport by encorafenib, increasing substrate exposure.
What to do
Monitor blood pressure and tolerability. Reduce the dipyridamole dose if adverse effects occur.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Dipyridamole and Encorafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Dipyridamole
- Dipyridamole + Riociguat Contraindicated
- Adenosine + Dipyridamole Major
- Betrixaban + Dipyridamole Major
- Dabigatran + Dipyridamole Major
- Dipyridamole + Regadenoson Major
- Dipyridamole + Venetoclax Major
Other interactions of Encorafenib
Frequently asked questions
Can I take Dipyridamole with Encorafenib?
MediHelp rates the interaction as minor. Dipyridamole and Encorafenib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Encorafenib may inhibit BCRP, and dipyridamole is a BCRP substrate. Exposure to dipyridamole could rise modestly, increasing its vasodilatory effects such as headache, hypotension and dizziness.
How serious is the interaction between Dipyridamole and Encorafenib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood pressure and tolerability. Reduce the dipyridamole dose if adverse effects occur.
What other medicines interact with Dipyridamole?
MediHelp also lists interactions of Dipyridamole with, for example, Riociguat, Adenosine, Betrixaban. The full list is on the Dipyridamole page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
